Veterinary Oncology Services for Pets

Cancer is diagnosed in approximately 6 million dogs and 6 million cats in the United States every year, according to the National Cancer Institute's comparative oncology program. Veterinary oncology is the medical specialty dedicated to diagnosing and treating those animals — a field that has advanced dramatically over the past two decades, borrowing heavily from human medicine while developing protocols specific to animal physiology. This page covers what veterinary oncology services actually involve, how treatment pathways unfold, when they make sense, and how families navigate the harder decisions.

Definition and scope

Veterinary oncology sits within the broader landscape of animal care veterinary services as a board-certified specialty recognized by the American College of Veterinary Internal Medicine (ACVIM). Diplomates in oncology complete a residency of three or more years after veterinary school, focusing exclusively on cancer biology, chemotherapy protocols, surgical oncology, and radiation medicine. There are roughly 350 board-certified veterinary oncologists practicing in the United States — a meaningful number, but one that creates real geographic concentration in urban academic centers and specialty hospitals.

The scope covers three primary treatment modalities: medical oncology (systemic drugs), surgical oncology (tumor removal and reconstructive procedures), and radiation oncology (external beam and stereotactic radiosurgery). Veterinary oncologists also perform diagnostic procedures including bone marrow biopsies, fine-needle aspirates, flow cytometry, and advanced imaging interpretation — the same toolkit a human hematologist or surgical oncologist would reach for.

How it works

A standard oncology consultation begins with biopsy and staging — determining not just what type of cancer is present, but whether and where it has spread. Staging typically involves a combination of radiographs, abdominal ultrasound, CT imaging, and sometimes lymph node sampling. This process can take several days and may cost between $500 and $2,000 before any treatment begins, depending on the modality required and the region of the country.

From staging, the oncologist proposes a treatment plan with defined goals. The distinction between curative intent and palliative intent is one of the most important frameworks in veterinary oncology:

Curative-intent protocols aim for complete remission or surgical cure. These are appropriate when the cancer type has known response rates to treatment and when the patient is otherwise healthy enough to tolerate aggressive therapy.
Palliative-intent protocols prioritize quality of life and comfort over aggressive disease control. These are appropriate when cure is unlikely, when a pet's overall health cannot support intensive treatment, or when the family's goals center on maximizing good days rather than extending total days.
Metronomic chemotherapy — continuous low-dose oral chemotherapy at home — occupies a middle ground, offering tumor control with reduced side-effect burden. It is increasingly used in dogs with soft tissue sarcomas and certain carcinomas.

Unlike human chemotherapy, veterinary chemotherapy protocols are typically calibrated to minimize side effects rather than maximize dose intensity. The goal is an animal that feels well enough to maintain normal behavior throughout treatment. The American Animal Hospital Association (AAHA) publishes oncology care guidelines that form the clinical baseline for this approach.

Common scenarios

Dogs develop mast cell tumors more than any other cancer type — accounting for roughly 20% of all skin tumors in dogs, according to Merck Veterinary Manual data. Treatment ranges from surgical excision alone (for low-grade tumors with clean margins) to combination protocols involving the tyrosine kinase inhibitor toceranib phosphate (Palladia), which became the first drug approved by the FDA specifically for a veterinary cancer in 2009.

Lymphoma in dogs is the scenario most owners encounter unexpectedly: a dog presents with swollen lymph nodes, and within a week the family is discussing a CHOP-based chemotherapy protocol (cyclophosphamide, doxorubicin, vincristine, and prednisone). The CHOP protocol achieves complete remission in approximately 80–90% of dogs with multicentric lymphoma, with median remission times around 12 months (ACVIM Consensus Statement on Canine Lymphoma).

Cats present differently. Feline injection-site sarcoma and intestinal lymphoma are among the most common oncology referrals in cats. Intestinal small-cell lymphoma in cats is notably responsive to oral chlorambucil and prednisone, with median survival times exceeding 700 days reported in peer-reviewed literature — a remarkably favorable outcome that surprises owners who hear "cancer" and assume the worst.

Radiation oncology is most relevant for tumors that cannot be fully resected surgically — nasal tumors, oral melanomas, brain tumors, and incompletely excised soft tissue sarcomas. Stereotactic radiosurgery (SRS), available at a growing number of university and private referral centers, delivers high-dose radiation with sub-millimeter precision in one to three sessions, reducing anesthesia events compared to conventional fractionated radiation.

Decision boundaries

The decision to pursue specialty oncology care — rather than palliative management with a primary care veterinarian — hinges on several converging factors. Cancer type and grade matter enormously: a low-grade, completely excised mast cell tumor may require nothing further, while an incompletely excised high-grade tumor at the same site warrants immediate oncology referral.

Pet age and baseline health are separate variables from cancer diagnosis. A 14-year-old dog with concurrent renal disease and cardiac arrhythmia faces different risk calculus than a 6-year-old dog with the same tumor type. Senior animal care considerations intersect with oncology decisions in ways that primary care veterinarians and oncologists must address together.

Cost is a legitimate decision boundary, not a moral failing. A full CHOP protocol for canine lymphoma costs between $3,000 and $8,000 over six months at most specialty centers. Animal care insurance options and financial assistance programs exist and are worth evaluating before assuming oncology is categorically out of reach.

Finally, the emotional weight of these decisions benefits from the same framework applied to end-of-life considerations more broadly: quality of life metrics, the animal's demonstrated daily experience, and the family's capacity to sustain intensive care. Veterinary oncologists routinely incorporate quality-of-life assessment tools — including the HHHHHMM Scale developed by palliative care veterinarian Alice Villalobos — as an ongoing part of treatment monitoring rather than a one-time conversation at diagnosis.